myTomorrows’ Post

We are delighted to announce one of the biggest milestones in our mission to transform chronic wound care — our CLEANVLU Phase IIa clinical trial report, which demonstrates proof-of-concept and safety of Aurase Wound Gel in humans, has now been published in International Wound Journal. Aurase Wound Gel aims to provide, for the first time, a safe, pain-free, and effective treatment for millions of people suffering from chronic wounds worldwide, and we are incredibly excited to be progressing this product through further Phase II studies. Our Chairman of the Board, Andy Weymann, MD, MBA, comments: “The peer-review publication of our Phase IIa data not only provides important validation to enable further Phase II studies, but also highlights the clinical potential of Aurase Wound Gel to treat millions of patients globally safely and effectively, addressing an urgent and unmet medical need. With this excellent data we are now fundraising to support the next phase of SolasCure’s clinical and product development.” Learn more here: https://lnkd.in/d4EbWtYd #WoundCare #ChronicWounds #ClinicalTrials #HealthCare

After watching the The White House Clinical Trials Forum and as someone who has witnessed the impact of clinical trials firsthand, I feel compelled to share my thoughts on this crucial topic. Our colleague, Monica's brave battle with cholangiocarcinoma has opened my eyes to the urgent need for more accessible clinical trials, especially for rare and aggressive cancers. Clinical trials are often the last beacon of hope for patients facing life-threatening illnesses, yet many are unaware of their existence or face significant barriers to participation. We need to do better in educating both patients and doctors about available trials and their potential benefits. I'm encouraged by the recent FDA release of the Diverse Access to Enrollment Action Plan, which aims to increase diversity in clinical trial participation. This is a step in the right direction, but we must go further. We need to ease eligibility criteria, rethink the use of placebos in certain cases, and make trials more patient-centric. Organizations like the Cholangiocarcinoma Foundation, recently seen on the panel at the White House Clinical Trials Forum, are doing incredible work in advocating for patients and pushing for more accessible trials. Their efforts are crucial, especially for lesser-known cancers that often receive less attention and funding. >>link to White House Clinical Trials Forum from June 26,2024 https://lnkd.in/d6BjtDGx >>link to the Diverse Access to Enrollment Action https://lnkd.in/dzzQu4JH #ClinicalTrials #PatientAdvocacy #CholangiocarcinomaAwareness #AccessibleHealthcare

SMS Clinical Research Celebrates Enrolling the 100th Patient in UTI Vaccine Study! We are thrilled to announce that we have enrolled our 100th patient in our UTI vaccine study! This achievement is a testament to our team's relentless dedication and hard work. We extend our heartfelt gratitude to our incredible team, participants, and sponsors for their unwavering support. Join us in celebrating this significant milestone and learn more about how SMS Clinical Research is paving the way for innovative clinical trials. Discover more about our groundbreaking research and how we can support your clinical trial needs: Clinical Trials in Mesquite, TX | SMS Clinical Research #UTIVaccine #JoinUs #HealthcareInnovation #BeAPartOfTheSolution #Mesquite #SMSClinicalResearch #HealthyLiving #ClinicalTrial #PatientCare #MedicalResearch #ClinicalTrials #Covid19 #HealthScience #ClinicalStudy #ResearchTrial #PatientCare #HealthCare #Treatment #Eczema

"There Was No Opportunity to Express Good or Bad" - quote from a patient in our clinical trial participant focus group research conducted with diverse patients in oncology, neurology and chronic disease. To learn more, check out our recent publication in the Journal of Patient Experience below. This data and other research our survey scientists conducted, were pivotal in forming our standardized measures of Patient Experience in Clinical Trials (PXCT) which are being validated across >45 trials in the US. Once complete, these measures will not only help retain patients and diversity in trials, but also define patient centricity and introduce new KPIs based on the patient voice. Special thanks to Savvy Cooperative for their support in this research. You Can't Improve What You Don't Measure! #PXCT #patientexperience #DEI #publication #psychometricassessments #clinicaltrials #clinicalresearch

Key Points in Sage's recent article regarding perspectives from #patient #focusgroups on #patientexperience in #clinicaltrials: •#Patientcentricity is critical in facilitating trust and #patientengagement during #clinicaltrials. •#Patients enrolled in #clinicaltrials want to be asked about their experience. •Regular and frequent communication with #patients should occur, even after trial completion. •#Patientcentric resources, for example, user-friendly technology, transportation, and on-site support, can impact #patientexperience. Savvy Cooperative, Press Ganey, PG Forsta

I was recently invited to share my insights with Brian Bossetta regarding the FDA’s new initiative aimed at advancing clinical trial diversity. The FDA's Oncology Center of Excellence (OCE) has launched an Equity Program to improve access to oncology clinical trials for historically marginalized groups, including racial and ethnic minorities, rural populations, and those facing barriers to healthcare access. The initiative is a significant step towards reducing health disparities and ensuring that all patients have the opportunity to participate in potentially life-saving trials. If oncology clinical trial participants do not adequately reflect the diverse groups of people who are affected by cancer, there is a risk of developing treatments that may be less effective or have different side effects for certain ethnic or racial groups. It may also perpetuate existing health disparities and limit access to cutting-edge therapies for these communities. Read my full discussion with Citeline's Medtech Insight here: https://lnkd.in/eUbBv94e

As we are getting ready for Clinical Trials Day... Here's just one of the countless reasons we should celebrate everyone who plays a critical role in clinical trials! 🙌 ACRP - Association of Clinical Research Professionals #patients #clinicaloperations #medicalaffairs #clinicalresearchers #ClinicalTrialsDay #CTD2024 #clinicaltrials #QoL #QualityofLife

The Myeloma and AL Amyloidosis European Clinical Trial Navigator is a powerful online tool by Myeloma Patients Europe (MPE). This platform helps you find clinical trials for myeloma, MGUS, smouldering myeloma (SMM), and AL amyloidosis across Europe. For patients, the tool supports informed discussions with healthcare professionals on trial options and empowers advocates to push for better clinical trial access at national levels. Learn more in the link below https://lnkd.in/dDRHsv2Z #MyelomaAdvocacy #ClinicalTrials #MPE #MPENavigator #EuropeanMyelomaDay

There’s still time to register for our webinar discussing the evolution of clinical trials, and how patient engagement will lead to better outcomes. #alifeinaday #patientfocus #webinar #clinicaltrials #improveoutcomes #patientengagement

📹 In this part of her video interview with Applied Clinical Trials Magazine, Sonia Lwoff, director, clinical operations, Rho, offers her thoughts on key considerations that sponsors should be mindful of during the decision-making process with the timeline of a clinical trial